BPC-157 vs GHK-Cu
Body Protection Compound · Copper Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
BPC-157
Promotes blood vessel formation and growth factor signaling at injury sites; the most-studied tissue repair peptide in animal models.
GHK-Cu
Delivers copper to tissue cells and modulates over 4,000 genes including those that build collagen; available in cosmetic and research formulations.
BPC-157
212 studies
4 human trials
Not FDA-Approved
GHK-Cu
186 studies
4 human trials
Not FDA-Approved
What it does
BPC-157
In animal studies, drives new blood vessel formation at injury sites, one of the body's main repair signals in damaged tissue. A short peptide fragment originally isolated from human stomach juice that, in rodent models, ramps up production of growth factors involved in healing (VEGF, EGF, FGF). The angiogenic effect documented in those animal studies is what underlies the recovery claims that made BPC-157 prominent in athletic and post-surgical contexts. Published human evidence remains essentially absent.
GHK-Cu
Delivers copper to skin and tissue cells, where it switches on the genes that build collagen and switches off the ones that drive aging. Naturally produced by the body; levels decline about 60 percent between the 20s and 60s.
How it works
BPC-157
A copy of a small protein the body naturally makes in the stomach. It works by turning up three repair signals (VEGF, EGF, FGF) that tell the body to build new blood vessels. It also nudges the nitric oxide system, which controls blood flow and inflammation. In animal research, the result is the body's own repair process running faster.
GHK-Cu
GHK-Cu binds copper(II) and delivers it to tissue sites where copper-dependent enzymes drive repair: lysyl oxidase for collagen cross-linking, superoxide dismutase for antioxidant defense, cytochrome c oxidase for cellular energy. It also directly modulates gene expression, upregulating collagen production and stem cell recruitment while downregulating the matrix-degrading enzymes that drive aging. The breadth of gene regulation (over 4,000 genes in transcriptomic studies) is unmatched among peptides, but gene expression changes in laboratory studies are not the same as clinical outcomes in humans.
How often
BPC-157
In studies, given as a daily shot under the skin, usually for several weeks at a time. Some studies have looked at oral forms specifically for gut work.
GHK-Cu
Topical application in cosmetic skincare formulations with decades of commercial use history. Injectable form expected to return to legal pharmacy preparation status following the February 2026 HHS announcement. Published human research is topical; no consensus injectable dosing protocol exists in peer-reviewed literature.
How strong
BPC-157
Local. The action concentrates at the injury rather than spreading body-wide.
GHK-Cu
The widest gap between mechanistic promise and clinical validation of any compound in PSI's library. Over 4,000 genes modulated in transcriptomic analysis (Pickart and Margolina 2018). Topical cosmetic studies show measurable skin improvements. Zero controlled human trials for injectable systemic use. The mechanism is real; the human systemic evidence is not yet there.
Main tradeoff
BPC-157
Strong animal data on tendons and gut healing. Human studies are thin. And one quirk: most of the published research traces back to a single research group, which limits how independent the findings are.
GHK-Cu
Topical GHK-Cu shows measurable improvements in skin thickness, elasticity, and fine lines in cosmetic studies. The copper-binding mechanism and gene expression profile are well-characterized across multiple independent research groups. Whether injectable GHK-Cu produces systemic anti-aging effects in humans is not established. Long-term safety of regular injectable administration is not characterized. As a naturally occurring peptide that declines approximately 60% between the 20s and 60s, the theoretical safety profile is favorable, but theoretical safety is not established safety.
Best for
BPC-157
- Research on a specific local injury: tendons, ligaments, or gut lining
- Research targeting one site rather than a body-wide effect
- Research using daily subcutaneous injection
GHK-Cu
- Research interest in copper-peptide mechanisms and broad gene modulation
- Research comparing topical versus systemic delivery of naturally occurring repair peptides
- Research contexts where the gap between transcriptomic promise and clinical validation is the central question
How to choose
A good fit for BPC-157
- Research on targeted growth factor signaling at specific injury sites (gut, tendon, ligament)
- Research on angiogenesis-driven tissue repair mechanisms
- Research contexts where the depth of animal model data matters most
A good fit for GHK-Cu
- Research on broad gene modulation through copper delivery to tissue
- Research on collagen synthesis and skin repair with both topical and systemic pathways
- Research contexts where human cosmetic efficacy data is relevant
Consider both across time
BPC-157 and GHK-Cu target tissue repair through different mechanisms that do not compete. BPC-157 works through focused growth factor signaling at injury sites (VEGF, EGF, FGF). GHK-Cu works through broad gene modulation via copper delivery. The two mechanisms address different bottlenecks in the repair process and are frequently combined in research protocols. Neither is FDA-approved. BPC-157 has deeper animal injury-model data; GHK-Cu has human cosmetic efficacy data and broader mechanistic profiling.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to NO System Modulation
- NO System Modulation upregulates VEGF / EGF / FGF
- VEGF / EGF / FGF connects to Blood Vessel Formation
- Blood Vessel Formation connects to Nutrient Delivery
- Copper(II) Delivery
- Copper(II) Delivery modulates TGF-beta Signaling
- Copper(II) Delivery activates Lysyl Oxidase Activation
- TGF-beta Signaling connects to Collagen Synthesis; Lysyl Oxidase Activation connects to Collagen Synthesis
- Copper(II) Delivery connects to MMP Suppression
- Collagen Synthesis connects to Tissue Remodeling; MMP Suppression connects to Tissue Remodeling
- Copper(II) Delivery connects to Broad Gene Modulation (4,000+)
BPC-157 increases growth factors (VEGF, EGF, FGF) that signal the body to build new blood vessels at the injury site.
GHK-Cu binds copper(II) and delivers it to tissue sites, where it modulates over 4,000 genes including those that build collagen.
Research Evidence
BPC-157 has the deeper preclinical injury-model evidence: multiple animal studies across tendon, ligament, muscle, gut mucosal, and bone repair showing accelerated healing. Human clinical data is limited to a small number of pilot studies. GHK-Cu has extensive mechanistic profiling (over 4,000 genes modulated) and published human cosmetic efficacy data for topical skin applications. Injectable systemic use data for GHK-Cu is more limited. Neither compound has completed the Phase III trials required for FDA approval.
- 1.
For tendon, ligament, or gut repair research, BPC-157 has significantly more relevant published data.
- 2.
For skin rejuvenation, collagen support, or topical wound healing. GHK-Cu is more directly studied for these applications.
- 3.
For deep tissue injury recovery, BPC-157 has the stronger preclinical evidence base.
- 4.
For anti-aging skin protocols. GHK-Cu is the more targeted compound.
Key Limitations
- •Direct head-to-head comparison studies do not exist.
- •BPC-157 research is heavily concentrated in one research group.
- •GHK-Cu research spans many formulations, making cross-study comparison difficult.
- •Neither compound has completed Phase III clinical trials.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
BPC-157
"BPC-157 healed my gut issues in two weeks"
Plausible but unproven in humans
"BPC-157 fixed my tendon injury faster than anything"
Plausible but unproven in humans
"BPC-157 is completely safe with no side effects"
Insufficient evidence
GHK-Cu
"GHK-Cu is the best anti-aging peptide for skin"
Plausible but unproven
"It regrew my hair"
Anecdotal only
"Topical is just as effective as injections"
Anecdotal only
Safety Comparison
Both compounds have favorable preclinical safety profiles. BPC-157 is derived from a naturally occurring protein in gastric juice and has shown no significant adverse effects in published animal studies. GHK-Cu is an endogenous peptide present in human plasma that declines with age. Topical GHK-Cu has been used in cosmetic products with a well-characterized safety profile. Neither compound has long-term human safety data from controlled trials for systemic injectable use.
BPC-157
Extensive animal safety data with no reported toxicity at therapeutic doses. Two human pilot studies published (2024-2025) with no serious adverse events. Not FDA-approved.
GHK-Cu
Well-tolerated in topical applications. Limited safety data for injectable use. Generally considered low-risk based on its endogenous nature, your body already makes GHK.
What the Research Suggests
These are different tools for different jobs. Comparing them is like comparing a plumber and an electrician, both fix things, but in completely different systems. BPC-157 for internal tissue repair. GHK-Cu for skin and collagen biology.